DAVID B SOLIT, MD
Osteopathic Medicine at York Ave, New York, NY

2012030, Nov 29, 2012

May 24, 2012

13/480050

Neal ROSEN - Englewood NJ, US
Poulikos Poulikakos - New York NY, US
David Solit - New York NY, US

C12Q 1/68

435 611, 435 612

The present invention provides methods and compositions for the detection of novel BRAF splice variants that mediate resistance to BRAF and/or pan-RAF inhibitors. In particular, the invention provides PCR primer(s) to be used in the disclosed methods of detection. In some embodiments, the compositions and methods of the present invention are used to predict resistance to BRAF and/or pan-RAF inhibitors in a subject suffering from or suspected of having cancer and further provides alternative treatment strategy(ies) for a subject, predicted to be resistant to BRAF and/or pan-RAF inhibitors. In a further embodiment, methods and composition for the identification of novel agents useful to overcome resistance to BRAF and/or pan-RAF inhibitors are disclosed. The present invention also provides isolated polynucleotide sequences of novel 5′ BRAF splice variant(s) and proteins produced from such polynucleotide sequences as well as cell line(s) that endogenously or exogenously express the splice variant(s).

2002009, Jul 11, 2002

Aug 24, 2001

09/938754

Samuel Danishefsky - Englewood NJ, US
Robert Garbaccio - Lansdale PA, US
Daniel Baeschlin - Arlesheim, CH
Shawn Stachel - Perkasie PA, US
David Solit - New York NY, US
Neal Rosen - Englewood NJ, US

C07D313/20, A61K031/335

514/450000, 549/269000

The present invention relates to compounds having the structure (I) (and pharmaceutically acceptable derivatives thereof) wherein R-R, Z, X, A-B, D-E, G-J, and K-L are as defined herein, the synthesis thereof and the use of these compounds as therapeutic agents.